Kanvas Biosciences has raised $48 million in a Series A round co-led by DCVC and Lions Capital, bringing total funding to $78 million. Gates Foundation, ATHOS KG, Germin8, Ki Tua Fund and Pangaea Ventures also participated. The spatial biology company will use the funds to conduct clinical trials for KAN-001, its lead immuno-oncology drug candidate designed to improve immunotherapy efficacy in solid organ cancer patients. The live biotherapeutic product addresses limitations of fecal microbiota transplants by offering safer, more scalable treatment for patients who don't respond to immune checkpoint inhibitors. Kanvas has developed a platform that spatially maps microbial and host cells, enabling manufacture of complex microbial consortia to restore microbiome health. The company recently opened a GMP manufacturing suite and is preparing to recruit patients for a Phase 1 trial.

CisLunar Industries has raised $2.6 million in an oversubscribed seed round led by Colorado ONE Fund, with participation from Stout Street Capital, RIT Venture Fund, Deming Center Venture Fund and strategic angel investors. Founded in 2019, the Loveland, Colorado-based company develops power electronics for space applications through its Electric Power Intelligent Conversion product line. The technology reduces lead times and engineering costs whilst increasing efficiency for spacecraft systems including electric propulsion, directed energy and nuclear power applications. CisLunar Industries' customers include NASA, United States Space Force, three defence contractors and ThinkOrbital. The funding will support continued development and expanded production of its power conversion systems for Earth orbit and beyond.